Featured Research

from universities, journals, and other organizations

Novel Gene Therapy Approach For Cystic Fibrosis In First Human Trials

Date:
April 4, 2002
Source:
University Hospitals Of Cleveland
Summary:
A 33-year old cystic fibrosis patient underwent the first gene therapy trial today using a novel approach to fight a deadly genetic disease that affects more than 30,000 Americans. The researchers include a team from The Research Institute of University Hospitals of Cleveland, its Rainbow Babies & Children’s Hospital, Case Western Reserve University School of Medicine, and Copernicus Therapeutics Inc., developers of the novel gene transfer system.

CLEVELAND, April 2, 2002 -- A 33-year old cystic fibrosis patient underwent the first gene therapy trial today using a novel approach to fight a deadly genetic disease that affects more than 30,000 Americans. The researchers include a team from The Research Institute of University Hospitals of Cleveland, its Rainbow Babies & Children’s Hospital, Case Western Reserve University School of Medicine, and Copernicus Therapeutics Inc., developers of the novel gene transfer system.

Related Articles


“Over the last decade, there have been various attempts to transfer healthy genes into the cells of the airways of cystic fibrosis patients,” explains primary investigator Michael W. Konstan, MD, Director of the LeRoy Matthews Cystic Fibrosis Center at Rainbow Babies & Children’s Hospital, and associate professor of pediatrics at CWRU School of Medicine. “Most of these trials have involved the use of a viral vector, attaching the healthy gene to a virus that will invade cells. Unfortunately, the virus itself has caused troublesome inflammation in the study patients.”

For more than a decade, UHC/CWRU researchers have explored alternative methods to viral vectors. Their work led to a patented approach produced by the Cleveland-based biotechnology firm, Copernicus Therapeutics, Inc. They developed a way to “compact” or tightly bind strands of DNA so that it is tiny enough to pass into the cell and then into the nucleus. Once inside a cell, researchers hope that the DNA will produce the normal version of the protein needed by cystic fibrosis patients.

Thirteen years ago, scientists discovered the cystic fibrosis (CF) gene. This defective gene upsets a delicate salt/water balance in the lungs. At the crux of the process is a protein, produced by the CF gene, which controls the flow of salt and water in and out of cells. In CF patients, this protein does not operate normally in the cells that line the airways. In turn, the airways accumulate thick and sticky mucus. Bacteria proliferate in the mucus and cause chronic infections that permanently damage lungs.

Under the direction of Dr. Konstan, the research team delivered the healthy gene into CF patient Robert Calhoun in a saline solution dripped slowly into his nasal passages. Investigators monitor the salt transport in his nose, called “nasal potential difference,” as a barometer of the procedure’s success. “CF patients have a markedly abnormal nasal potential difference,” Dr. Konstan says. First, through biopsies of nasal tissue, researchers will determine whether the healthy gene was “taken up” by the cells. Then, if the DNA produces enough protein, there should be a change in the transport of salt and water in and out of the cells, which can be measured by the nasal potential difference test.

“This is a terrific example of the style of translational research that goes on at The Research Institute, bringing advances from the lab to improvements in health care”, commented Huntington F. Willard, Ph.D., President and Director of the Research Institute of University Hospitals of Cleveland. “It also illustrates the strength of combining research efforts at the hospital, the university and industry. This kind of three-way collaboration is essential for transferring our discoveries to the public.”

University Hospitals is the lead center for this study, and will enroll 12 patients with CF. The second site, Children’s Hospital of Denver in Colorado, will send a team to Cleveland later in the spring to observe the procedures before they begin enrollment.

This DNA compaction technology was developed at Copernicus Therapeutics and is based on initial discoveries in the laboratory of Pamela B. Davis, MD, Ph.D., Director of the Willard A. Bernbaum Cystic Fibrosis Research Center and professor of pediatrics at Rainbow Babies & Children’s Hospital and CWRU, and by Jose C. Perales, Ph.D., a former graduate student in the laboratory of Richard W. Hanson, Ph.D., professor of biochemistry at CWRU. Dr. Davis, Hanson and Perales are inventors of numerous patents assigned to CWRU School of Medicine. The study is funded in part by The Cystic Fibrosis Foundation.

###

University Hospitals Health System (UHHS) is the region’s premier healthcare delivery system, serving patients at more than 150 locations throughout northern Ohio.

The System's 947-bed, tertiary medical center, University Hospitals of Cleveland (UHC), is the primary affiliate of Case Western Reserve University. Together, they form the largest center for biomedical research in the State of Ohio. The System provides the major clinical base for translational researchers at The Research Institute of University Hospitals of Cleveland, as well as a broad and well-characterized patient population for clinical trials involving the most advanced treatments. Included in UHC are Rainbow Babies & Children's Hospital, among the nation's best children’s hospitals; Ireland Cancer Center, northern Ohio's only National Cancer Institute-designated Comprehensive Cancer Center (the nation’s highest designation); and MacDonald Women's Hospital, Ohio's only hospital for women.

Committed to advanced care and advanced caring, University Hospitals Health System offers the region’s largest network of primary care physicians, outpatient centers and hospitals. The System also includes a network of specialty care physicians, skilled nursing, elder health, rehabilitation and home care services, managed care and insurance programs, and the most comprehensive behavioral health services in the region.


Story Source:

The above story is based on materials provided by University Hospitals Of Cleveland. Note: Materials may be edited for content and length.


Cite This Page:

University Hospitals Of Cleveland. "Novel Gene Therapy Approach For Cystic Fibrosis In First Human Trials." ScienceDaily. ScienceDaily, 4 April 2002. <www.sciencedaily.com/releases/2002/04/020403024915.htm>.
University Hospitals Of Cleveland. (2002, April 4). Novel Gene Therapy Approach For Cystic Fibrosis In First Human Trials. ScienceDaily. Retrieved November 23, 2014 from www.sciencedaily.com/releases/2002/04/020403024915.htm
University Hospitals Of Cleveland. "Novel Gene Therapy Approach For Cystic Fibrosis In First Human Trials." ScienceDaily. www.sciencedaily.com/releases/2002/04/020403024915.htm (accessed November 23, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Sunday, November 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola-Hit Sierra Leone's Late Cocoa Leaves Bitter Taste

Ebola-Hit Sierra Leone's Late Cocoa Leaves Bitter Taste

AFP (Nov. 23, 2014) The arable district of Kenema in Sierra Leone -- at the centre of the Ebola outbreak in May -- has been under quarantine for three months as the cocoa harvest comes in. Duration: 01:32 Video provided by AFP
Powered by NewsLook.com
Don't Fall For Flu Shot Myths

Don't Fall For Flu Shot Myths

Newsy (Nov. 23, 2014) Misconceptions abound when it comes to your annual flu shot. Medical experts say most people older than 6 months should get the shot. Video provided by Newsy
Powered by NewsLook.com
WFP: Ebola Risks Heightened Among Women Throughout Africa

WFP: Ebola Risks Heightened Among Women Throughout Africa

AFP (Nov. 21, 2014) Having children has always been a frightening prospect in Sierra Leone, the world's most dangerous place to give birth, but Ebola has presented an alarming new threat for expectant mothers. Duration: 00:37 Video provided by AFP
Powered by NewsLook.com
Could Your Genes Be The Reason You're Single?

Could Your Genes Be The Reason You're Single?

Newsy (Nov. 21, 2014) Researchers in Beijing discovered a gene called 5-HTA1, and carriers are reportedly 20 percent more likely to be single. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins